TOKYO, Japan – RIBOMIC, Inc. (TOKYO:4591), a clinical-stage pharmaceutical company specializing in aptamer therapeutics, has conducted a Phase 2 clinical trial of umedaptanib pegol (anti-FGF2 aptamer) in pediatric patients (ages 5-14) with achondroplasia (ACH). The company announced today that the administration of the high-dose (0.6 mg/kg) subcutaneous injection (once biweekly)...
Latest News
HOUSTON, Texas – Rice University bioengineers have developed a new construction kit for building custom sense-and-respond circuits in human cells. The research, published in the journal Science, represents a major breakthrough in the field of synthetic biology that could revolutionize therapies for complex conditions like autoimmune disease and cancer. “Imagine...
Houston, TX – Cancers begin with abnormal changes in individual cells, and the ability to track the accumulation of mutations at the single-cell level can shed new light on the early stages of the disease. Such knowledge could enable more effective early detection and treatment options for patients as well...
SOUTH SAN FRANCISCO, Calif. — Rigel Pharmaceuticals, Inc. today announced a collaboration with CONNECT, an international collaborative network of pediatric cancer centers, to conduct a Phase 2 clinical trial to evaluate REZLIDHIA® (olutasidenib) in combination with temozolomide as maintenance therapy in newly diagnosed pediatric and young adult patients with high-grade glioma...
SOUTH SAN FRANCISCO, Calif. — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a peer-reviewed publication in Leukemia & Lymphoma on data from an analysis of the Phase 2 study evaluating REZLIDHIA® (olutasidenib), a potent, selective, oral, small-molecule inhibitor of mutant isocitrate dehydrogenase-1 (mIDH1), in patients with mIDH1 acute myeloid leukemia (AML) who were relapsed/refractory...
SOUTH SAN FRANCISCO, Calif. — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that its oral Syk inhibitor, R788, is being evaluated in a Phase 2 clinical trial funded, designed and implemented by the National Cancer Institute (NCI), part of the U.S. National Institutes of Health. This open-label, single arm clinical...
Riociguat may be a useful option for patients with pulmonary arterial hypertension (PAH) in whom phosphodiesterase-5 inhibitor (PDE5i) treatment is insufficient, according to the results of a recent study published in the journal Lancet Respiratory Medicine. Researchers evaluated clinical improvement, defined as an absence of clinical worsening and prespecified improvements in...
Colorectal cancer rates are rising in adults younger than 50 with the biggest jump, more than 5 percent, recorded in those ages 20 to 29, a study found. People older than age 50 began getting tested routinely for the disease in the mid-1980s, leading to a 2.8 percent yearly decline...
Kuopio, Finland – A risk model developed by researchers can help to identify cancer patients who could benefit from immune checkpoint inhibitors, ICIs. Published in BMC Cancer, the study was conducted at the University of Eastern Finland and Kuopio University Hospital. Immune checkpoint inhibitors are used to treat a variety...
Mention of valley fever is liable to touch off quizzical looks or bad jokes, but to those who have it or are close to someone with it, it is no laughing matter. Life for Lake Elsinore resident Araceli Jimenez underwent a drastic change after her husband came down with the...